Commerzbank Aktiengesellschaft FI Has $5.51 Million Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Commerzbank Aktiengesellschaft FI increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 15.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 11,131 shares of the medical equipment provider's stock after purchasing an additional 1,485 shares during the quarter. Commerzbank Aktiengesellschaft FI's holdings in Intuitive Surgical were worth $5,513,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. AlphaCore Capital LLC boosted its stake in Intuitive Surgical by 4.2% in the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock valued at $235,000 after buying an additional 18 shares in the last quarter. Accredited Investors Inc. boosted its stake in shares of Intuitive Surgical by 1.9% during the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock valued at $543,000 after purchasing an additional 19 shares in the last quarter. Second Line Capital LLC boosted its stake in shares of Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after purchasing an additional 19 shares in the last quarter. Colonial Trust Co SC boosted its stake in shares of Intuitive Surgical by 8.8% during the fourth quarter. Colonial Trust Co SC now owns 246 shares of the medical equipment provider's stock valued at $128,000 after purchasing an additional 20 shares in the last quarter. Finally, Crown Wealth Group LLC lifted its stake in shares of Intuitive Surgical by 4.8% in the first quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock worth $218,000 after acquiring an additional 20 shares during the period. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $512.64 on Thursday. Intuitive Surgical, Inc. has a 52-week low of $413.82 and a 52-week high of $616.00. The firm has a market capitalization of $183.74 billion, a P/E ratio of 75.17, a P/E/G ratio of 5.43 and a beta of 1.64. The stock has a 50 day moving average price of $536.71 and a 200-day moving average price of $536.21.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. The company had revenue of $2.25 billion during the quarter, compared to analyst estimates of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same quarter last year, the company earned $1.50 EPS. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, EVP Gary Loeb sold 1,700 shares of Intuitive Surgical stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $513.18, for a total value of $872,406.00. Following the sale, the executive vice president directly owned 2,245 shares of the company's stock, valued at approximately $1,152,089.10. The trade was a 43.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jami K. Nachtsheim sold 2,400 shares of Intuitive Surgical stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the sale, the director directly owned 6,371 shares in the company, valued at $3,312,920. This trade represents a 27.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,998 shares of company stock valued at $2,611,577. Corporate insiders own 0.70% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on ISRG. Deutsche Bank Aktiengesellschaft lowered Intuitive Surgical from a "hold" rating to a "sell" rating and cut their price objective for the stock from $515.00 to $440.00 in a research note on Monday, June 9th. Erste Group Bank upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Thursday, June 5th. Royal Bank Of Canada decreased their price objective on Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Piper Sandler cut their target price on Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Finally, Truist Financial cut their target price on Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. One analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $592.86.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.